MedTrace Logo

Omalizumab in Severe Asthmatics With Food Allergy

NCT06316414 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2024-03-18

No results posted yet for this study

Summary

A prospective assessment of the impact of Omalizumab in terms of efficacy, safety, and quality of life (FA-QoL) in patients with moderate/severe asthma and history of anaphylaxis to peanut, tree nuts, fish, egg, milk, and/or wheat. Evaluation of the trend of total and specific IgE during Omalizumab treatment.

Conditions

  • Food; Allergy, Anaphylactic Shock
  • Asthma in Children

Interventions

BIOLOGICAL

Omalizumab

Administration of Omalizumab at the doses indicated for asthma in the EMA information leaflet.

Sponsors & Collaborators

  • Bambino Gesù Hospital and Research Institute

    lead OTHER

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2023-03-31
Completion
2023-03-31
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06316414 on ClinicalTrials.gov